UW Medicine is unveiling an FDA-approved spinal cord therapy in an effort to offer new hope for paralyzed patients.
The regulator conducted a postmarketing trial which suggested increased risk of Guillain-Barré syndrome (GBS) 42 days ...
Makers of medical devices that quickly measure oxygen levels in the blood would have to gather extra data to show that their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback